<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01481025</url>
  </required_header>
  <id_info>
    <org_study_id>Cimicifuga/Herbarium</org_study_id>
    <nct_id>NCT01481025</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety for Cimicifuga/Hypericum Product</brief_title>
  <acronym>CH</acronym>
  <official_title>Phase 3 Study - Efficacy and Tolerance for the Mixture of Dry Extracts Black Cohosh and Saint John's Worth Versus Isolated Black Cohosh Extract for the Climacteric Symptoms' Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phytopharm Consulting Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herbarium Laboratório Botânico Ltda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Complexo Hospitalar Santa Casa de Misericordia de Porto alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Phytopharm Consulting Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Climacteric Complains bring to women many problems for living a normal life - hot flashes,
      irritation are 2 of many problems and the mixture of those 2 plant extract must bring a new
      horizon for this part of time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2 herbal extracts used in general alone will be running together for the best climacteric
      women on quality of life.

      The investigators will test the mixture already in the market as GynoPlus and RemifeminPlus,
      but as each extract has its own particularities the investigators will try CIM/HIP as a
      unique formulation versus Clifemin® as control and Aplause® as comparator.

      This protocol was performed for the best of our volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Menopause Rating Scale</measure>
    <time_frame>8 months</time_frame>
    <description>Climacteric Symptoms Evaluation - &quot;MRS - Menopause Rating Scale*</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton's Depression Scale</measure>
    <time_frame>8 months</time_frame>
    <description>Questionair for Depression Symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHOQOL</measure>
    <time_frame>8 months</time_frame>
    <description>Starting Point (T-2) and Ending Point (T6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Numbers</measure>
    <time_frame>8 months (T-2 to T6)</time_frame>
    <description>Starting Point (T0, T1, T3 and T6)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Perimenopausal Disorder</condition>
  <arm_group>
    <arm_group_label>Cimicifuga+Hiperico</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 + 450 mg / tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cimicifuga Herbarium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80 mg / caps</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aplause®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg / tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cimicifuga + Hiperico</intervention_name>
    <description>1 tablet, 80+450mg/tablet, twice a day for 1-3 months
1 tablet, 80+450mg/tablet, once a day for 3-6 months</description>
    <arm_group_label>Cimicifuga+Hiperico</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cimicifuga Herbarium</intervention_name>
    <description>2 caps, 80mg/caps, once a day for 1-3 months
1 caps, 80mg/caps, once a day for 3-6 months</description>
    <arm_group_label>Cimicifuga Herbarium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aplause®</intervention_name>
    <description>4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months</description>
    <arm_group_label>Aplause®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Climacteric women 45-60 years old - pre and postmenopausal

          -  Climacteric complains for at least 3 months

          -  No treatments for at least 2 months

          -  MRS score 0.4 or more for at least 3 items

          -  Hamilton's Scale score from 15-23

        Exclusion Criteria:

          -  Hormon Therapy or any other for the last 3 months

          -  Antidepressive and Hypnotic medication for the last 3 months

          -  Sever illness (cardiac, hepatic, renal, digestive or metabolic) or TSH alteration

          -  History for allergies and hipersensitivity to any component of the drugs formulations

          -  No knowledge for reading or writing

          -  Suicide risk
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karla F Deud José, Pharm PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Phytopharm Consulting Brazil - karla@phytopharm.com.br</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carla Vanin, MD MSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Health Science of Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raquel P Dibi, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Irmandade Santa Casa de Misericórdia de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marli Chaves, Secretary</last_name>
    <phone>+55 51 8130-8454</phone>
    <email>contato@phytopharm.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karla F Deud José, PharmD PhD</last_name>
    <phone>+55 51 9279-3075</phone>
    <email>karla@phytopharm.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ISCMPA's Gynecology Ambulatory</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marli Chaves, Secretary</last_name>
      <phone>+55 51 81308454</phone>
      <email>contato@phytopharm.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Gustavo Remus, Physical Edu</last_name>
      <phone>+55 51 9191-6535</phone>
      <email>remus@phytopharm.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Carla Vanin, MD MSc PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raquel P Dibi, MD MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2011</study_first_submitted>
  <study_first_submitted_qc>November 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <last_update_submitted>November 28, 2011</last_update_submitted>
  <last_update_submitted_qc>November 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Climacteric</keyword>
  <keyword>Depression</keyword>
  <keyword>Herbal treatment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

